Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
IMMUNIC, INC. (VTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Investor presentation
Docs: "Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis",
"Presentation"
08/03/2023 8-K Quarterly results
Docs: "Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update",
"Presentation"
06/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update"
05/04/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/05/2023 8-K Investor presentation
Docs: "Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis",
"Presentation"
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/23/2023 8-K Quarterly results
Docs: "Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update",
"Presentation"
02/09/2023 8-K Quarterly results
12/30/2022 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
10/11/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Immunic, Inc. Pre-Funded Warrant To Purchase Common Stock Warrant No.: ____________ Number of Shares of Common Stock: _____________ Date of Issuance: , 2022 Immunic, Inc., a company organized under the laws of Delaware , hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________], the registered holder hereof or its permitted assigns , is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price then in effect, at any time or times, up to ______________ fully paid non-assessable shares of Common Stock , subject to adjustment as provided herein . Except as otherwise defined herein, capitalized terms in this Pre-Funded Warrant to Purchase Common Stock , shall have the meaning...",
"SECURITIES PURCHASE AGREEMENT",
"Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing NEW YORK, October 10, 2022 – Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an aggregate of 8,696,552 shares of its common stock at a price of $4.35 per share, reflecting a 10% premium to the closing price on October 7, 2022 on NASDAQ, and pre-funded warrants to purchase up to an aggregate of 5,096,552 shares of Common Stock at a purchase price of $4.34 per pre-funded warrant share, through a private investment in publi..."
09/20/2022 8-K Investor presentation
Docs: "Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects",
"Presentation"
08/04/2022 8-K Quarterly results
Docs: "Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
07/07/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/21/2022 8-K Regulation FD Disclosure  Interactive Data
03/16/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "ADDENDUM NO. THREE TO EMPLOYMENT AGREEMENT"
02/24/2022 8-K Quarterly results
02/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn’ s and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis"
01/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Third Addendum, to Service Agreement between Immunic AG and Dr. Daniel Vitt",
"Third Addendum, to Service Agreement between Immunic AG and Dr. Andreas Muehler",
"Third Addendum, to Service Agreement between Immunic AG and Dr. Hella Kohlhof",
"Presentation"
12/14/2021 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity",
"Presentation"
10/15/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by Patrick Walsh and Immunic, Inc"
08/06/2021 8-K Quarterly results
Docs: "Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity"
07/19/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"Salans FMC SNR Denton"
07/12/2021 8-K Quarterly results
07/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy